100 related articles for article (PubMed ID: 11132239)
1. Sensitizing human colon carcinoma HT-29 cells to cisplatin by cyclopentenylcytosine, in vitro and in vivo.
Gharehbaghi K; Szekeres T; Yalowitz JA; Fritzer-Szekeres M; Pommier YG; Jayaram HN
Life Sci; 2000 Nov; 68(1):1-11. PubMed ID: 11132239
[TBL] [Abstract][Full Text] [Related]
2. Studies on the antitumor activity and biochemical actions of cyclopentenyl cytosine against human colon carcinoma HT-29 in vitro and in vivo.
Gharehbaghi K; Zhen W; Fritzer-Szekeres M; Szekeres T; Jayaram HN
Life Sci; 1999; 64(2):103-12. PubMed ID: 10069488
[TBL] [Abstract][Full Text] [Related]
3. 3'-ethynylcytidine, an RNA polymerase inhibitor, combined with cisplatin exhibits a potent synergistic growth-inhibitory effect via Vaults dysfunction.
Fukushima H; Abe T; Sakamoto K; Tsujimoto H; Mizuarai S; Oie S
BMC Cancer; 2014 Aug; 14():562. PubMed ID: 25087851
[TBL] [Abstract][Full Text] [Related]
4. Synergistic effect and possible mechanisms of tumor necrosis factor and cisplatin cytotoxicity under moderate hyperthermia against gastric cancer cells.
Buell JF; Reed E; Lee KB; Parker RJ; Venzon DJ; Amikura K; Arnold S; Fraker DL; Alexander HR
Ann Surg Oncol; 1997 Mar; 4(2):141-8. PubMed ID: 9084851
[TBL] [Abstract][Full Text] [Related]
5. Reversal by cytidine of cyclopentenyl cytosine-induced toxicity in mice without compromise of antitumor activity.
Ford H; Driscoll JS; Hao Z; Dobyns KA; Rommel ME; Stowe E; Anderson JO; Plowman J; Waud WR; Johns DG
Biochem Pharmacol; 1995 Jan; 49(2):173-80. PubMed ID: 7840794
[TBL] [Abstract][Full Text] [Related]
6. Resistance to cyclopentenylcytosine in murine leukemia L1210 cells.
Zhang H; Cooney DA; Zhang MH; Ahluwalia G; Ford H; Johns DG
Cancer Res; 1993 Dec; 53(23):5714-20. PubMed ID: 7694793
[TBL] [Abstract][Full Text] [Related]
7. The effect of cyclopentenyl cytosine on human SK-N-BE(2)-C neuroblastoma cells.
Slingerland RJ; Van Gennip AH; Bodlaender JM; Voûte PA; Van Kuilenburg AB
Biochem Pharmacol; 1995 Jul; 50(2):277-9. PubMed ID: 7632174
[TBL] [Abstract][Full Text] [Related]
8. Enhanced sensitivity of bladder cancer cells to cisplatin mediated cytotoxicity and apoptosis in vitro and in vivo by the selective cyclooxygenase-2 inhibitor JTE-522.
Mizutani Y; Nakanishi H; Li YN; Sato N; Kawauchi A; Miki T
J Urol; 2004 Oct; 172(4 Pt 1):1474-9. PubMed ID: 15371874
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo antineoplastic activity of a new platinum antineoplastic agent, (R)-(-)-1,1-cyclobutanedicarboxylate (2-aminomethylpyrrolidine)-platinum (II) (DWA2114R) on freshly separated human tumor cells and human tumor xenografts transplanted in nude mice--a comparison with cis-diammine-dichloroplatinum (CDDP).
Nio Y; Imai S; Shiraishi T; Tsubono M; Morimoto H; Tseng CC; Tobe T
Anticancer Res; 1991; 11(2):761-7. PubMed ID: 2064331
[TBL] [Abstract][Full Text] [Related]
10. Cyclopentenyl cytosine increases the phosphorylation and incorporation into DNA of 1-beta-D-arabinofuranosyl cytosine in a human T-lymphoblastic cell line.
Verschuur AC; Van Gennip AH; Leen R; Voûte PA; Brinkman J; Van Kuilenburg AB
Int J Cancer; 2002 Apr; 98(4):616-23. PubMed ID: 11920624
[TBL] [Abstract][Full Text] [Related]
11. Cellular pharmacology of cyclopentenyl cytosine in Molt-4 lymphoblasts.
Ford H; Cooney DA; Ahluwalia GS; Hao Z; Rommel ME; Hicks L; Dobyns KA; Tomaszewski JE; Johns DG
Cancer Res; 1991 Jul; 51(14):3733-40. PubMed ID: 1712247
[TBL] [Abstract][Full Text] [Related]
12. Chemoimmunosensitization of the T24 human bladder cancer line to Fas-mediated cytotoxicity and apoptosis by cisplatin and 5-fluorouracil.
Mizutani Y; Wu XX; Yoshida O; Shirasaka T; Bonavida B
Oncol Rep; 1999; 6(5):979-82. PubMed ID: 10425290
[TBL] [Abstract][Full Text] [Related]
13. Synergistic interaction between cisplatin and gemcitabine in vitro.
Bergman AM; Ruiz van Haperen VW; Veerman G; Kuiper CM; Peters GJ
Clin Cancer Res; 1996 Mar; 2(3):521-30. PubMed ID: 9816199
[TBL] [Abstract][Full Text] [Related]
14. Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system.
Light BW; Yu WD; McElwain MC; Russell DM; Trump DL; Johnson CS
Cancer Res; 1997 Sep; 57(17):3759-64. PubMed ID: 9288784
[TBL] [Abstract][Full Text] [Related]
15. Sensitization of human ovarian tumor cells by subtoxic CDDP to anti-fas antibody-mediated cytotoxicity and apoptosis.
Uslu R; Jewett A; Bonavida B
Gynecol Oncol; 1996 Aug; 62(2):282-91. PubMed ID: 8751562
[TBL] [Abstract][Full Text] [Related]
16. 1-(3-C-Ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106), a novel potent inhibitor of RNA polymerase, potentiates the cytotoxicity of CDDP in human cancer cells both in vitro and in vivo.
Kazuno H; Fujioka A; Fukushima M; Wataya Y; Matsuda A; Sasaki T
Int J Oncol; 2009 May; 34(5):1373-80. PubMed ID: 19360349
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide.
Mizutani Y; Fukumoto M; Bonavida B; Yoshida O
Cancer; 1994 Nov; 74(9):2546-54. PubMed ID: 7923012
[TBL] [Abstract][Full Text] [Related]
18. Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1.
Shang X; Lin X; Manorek G; Howell SB
Mol Pharmacol; 2013 Jan; 83(1):85-94. PubMed ID: 23053666
[TBL] [Abstract][Full Text] [Related]
19. Cyclopentenylcytosine does not enhance cisplatin-induced radiosensitization in human lung tumour cells.
Rodermond HM; Cate RT; Haveman J; VAN Kuilenburg A; Medema JP; VAN Bree C; Franken NA
Oncol Lett; 2010 May; 1(3):537-540. PubMed ID: 22966339
[TBL] [Abstract][Full Text] [Related]
20. JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin.
Fokkema E; Groen HJ; Helder MN; de Vries EG; Meijer C
Biochem Pharmacol; 2002 Jun; 63(11):1989-96. PubMed ID: 12093475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
